Dr. Kuykendall from EHA 2025: ‘the research is as hot as the conference center’
Andrew Kuykendall, MD, SOHO Insider MPN podcast host, and assistant professor in the Department of Malignant Hematology at Moffitt Cancer Center, delivers live
EHA 2025
Meetings / Conferences
Myeloproliferative Neoplasms
EHA 2025
News
FELIX post-hoc data reinforce obe-cel durability
A post-hoc analysis found that the chimeric antigen receptor T-cell therapy obecabtagene autoleucel (obe-cel) produced durable remissions and maintained a favorable benefit-risk profile
Leukemia
Young Investigator Program
Dr. Gonzalez Lugo reflects on the SOHO YIP award
Meet Jesus Gonzalez Lugo, MD, an assistant professor of medicine at the University of Kansas and a 2024 SOHO Young Investigator Program (YIP)
Leukemia
Acute Myeloid Leukemia
New immunotherapy approach may treat aggressive AML, MDS
Researchers conducted a proof-of-concept study for genetically redirecting T cells, offering a potential immunotherapy target for acute myeloid leukemia (AML) and myelodysplastic syndromes
ASCO 2025
Isatuximab with KRd boosts sustained MRD negativity in myeloma
Patients with newly-diagnosed multiple myeloma (MM) treated with isatuximab plus carfilzomib, lenalidomide, dexamethasone (IsaKRD) in induction, consolidation, and light consolidation phases saw sustained measurable
ASCO 2025
Sintilimab plus ICE regimen significantly improves complete remission in classical Hodgkin lymphoma
Sintilimab plus ifosfamide, carboplatin, and etoposide (ICE) as second-line treatment of classical Hodgkin lymphoma (cHL) significantly improved complete remission rates (CRRs) compared with
Leukemia
Chronic Myeloid Leukemia
Generic version of nilotinib enters US market for treatment of certain leukemias
A generic version of nilotinib (Tasigna®) entered the US market on May 27, 2025, with 180 days of exclusivity, reported Apotex, the pharmaceutical
ASCO 2025
Enrolling now: quizartinib plus standard therapy for newly-diagnosed AML
The phase 3 QuANTUM-Wild study is assessing the use of quizartinib plus standard induction/consolidation chemotherapy and maintenance therapy in newly-diagnosed patients with FLT3-ITD-negative acute
ASCO 2025
Meetings / Conferences
Phase 3 MIDAS trial assesses MRD-driven approach to consolidation, maintenance therapy in myeloma
A phase 3 study is assessing a measurable residual disease (MRD)-driven consolidation and maintenance strategy for patients with newly diagnosed multiple myeloma (NDMM).
Leukemia
Chronic Myeloid Leukemia
News
Making resistance futile: lessons from the fields
In this editorial, SOHO Insider Associate Editor Dr. Jerry Radich draws a parallel between cancer treatment and agricultural pest control.